Targeted therapies in early-stage breast cancer: achievements and promises

Surgical Oncology Clinics of North America
George W SledgeLida Mina

Abstract

One of the most impressive changes in the therapeutic landscape of breast cancer in the past decade has been the advent of targeted therapies for specific subtypes. This article discusses the meaning of targeted therapy and examines the genomic basis for targeted therapy as it has emerged over the past decade. Human epidermal growth factor receptor 2 (HER2)-targeted therapy, the principle example of targeted therapy to enter the adjuvant arena in the past decade, is described in depth. Novel targeted therapies under development, many currently being examined in the adjuvant setting, are also explored, including anti-vascular endothelial growth factor therapy, poly (ADP ribose) polymerase (PARP) inhibition for triple-negative breast cancers, and agents targeting site-specific metastasis to the bone (receptor activator of NF-kB [RANK] ligand inhibition). Chemotherapy, the epitome of nonspecific anticancer therapy, is in the process of becoming targeted therapy as understanding of breast cancer biology improves.

References

Dec 30, 1994·Biochimica Et Biophysica Acta·N E Hynes, D F Stern
Mar 21, 1998·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·D J Riese, D F Stern
May 9, 1998·Proceedings of the National Academy of Sciences of the United States of America·H YasudaT Suda
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·T SørlieA L Børresen-Dale
Dec 20, 2002·The New England Journal of Medicine·Marc J van de VijverRené Bernards
May 16, 2003·Nature·Shun-ichi Harada, Gideon A Rodan
Sep 10, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce E HillnerUNKNOWN American Society of Clinical Oncology
Dec 23, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·B LinderholmR Henriksson
Mar 12, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gottfried E KonecnyMark D Pegram
Apr 16, 2004·The New England Journal of Medicine·G David Roodman
Mar 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George W Sledge
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Oct 21, 2005·The New England Journal of Medicine·Edward H RomondNorman Wolmark
Feb 21, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jean-Jacques BodyPirow J Bekker
Feb 24, 2006·The New England Journal of Medicine·Heikki JoensuuUNKNOWN FinHer Study Investigators
Feb 24, 2006·The New England Journal of Medicine·Michael R McClungUNKNOWN AMG 162 Bone Loss Study Group
Mar 31, 2006·Nature·D Holstead JonesJosef M Penninger
May 25, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Soonmyung PaikNorman Wolmark
Oct 26, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert E Coleman
Dec 29, 2006·The New England Journal of Medicine·Charles E GeyerDavid Cameron
Sep 6, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Allan LiptonSusie Jun
Dec 28, 2007·The New England Journal of Medicine·Kathy MillerNancy E Davidson
Mar 18, 2008·Current Opinion in Genetics & Development·Sarah A MartinAlan Ashworth
Jul 4, 2008·Nature Reviews. Cancer·Lee M Ellis, Daniel J Hicklin
Aug 30, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Georgiana K EllisSusie Jun
Dec 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Bryan P SchneiderLisa A Carey
Jun 13, 2009·Breast Cancer Research : BCR·Bryan P Schneider, George W Sledge

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Related Papers

Current Opinion in Oncology
Gert StockmansRobert Paridaens
International Journal of Cancer. Journal International Du Cancer
M J DuffyJ Crown
Clinical Oncology : a Journal of the Royal College of Radiologists
E A Rakha, S Chan
© 2021 Meta ULC. All rights reserved